NASDAQ:LTGO Latigo Biotherapeutics Q2 2026 Earnings Report $22.48 +0.71 (+3.26%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Latigo Biotherapeutics EPS ResultsActual EPS-$27.59Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALatigo Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALatigo Biotherapeutics Announcement DetailsQuarterQ2 2026Date9/3/2026TimeAfter Market ClosesConference Call DateThursday, September 3, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Latigo Biotherapeutics Earnings HeadlinesLatigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights3 hours ago | globenewswire.comLatigo Biotherapeutics Inc LTGOSeptember 1 at 3:45 AM | morningstar.comMYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 3 at 1:00 AM | Profits Run (Ad)Latigo Biotherapeutics Inc.August 15, 2026 | barrons.comInside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes PublicAugust 13, 2026 | 247wallst.comInside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes PublicAugust 13, 2026 | 247wallst.comSee More Latigo Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Latigo Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Latigo Biotherapeutics and other key companies, straight to your email. Email Address About Latigo BiotherapeuticsLatigo Biotherapeutics (NASDAQ:LTGO) Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc. is based in THOUSAND OAKS, Calif.View Latigo Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
